BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32576651)

  • 1. High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy.
    Raghuvanshi R; Vasco K; Vázquez-Baeza Y; Jiang L; Morton JT; Li D; Gonzalez A; DeRight Goldasich L; Humphrey G; Ackermann G; Swafford AD; Conrad D; Knight R; Dorrestein PC; Quinn RA
    mSystems; 2020 Jun; 5(3):. PubMed ID: 32576651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease.
    Quinn RA; Lim YW; Mak TD; Whiteson K; Furlan M; Conrad D; Rohwer F; Dorrestein P
    PeerJ; 2016; 4():e2174. PubMed ID: 27602256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
    Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
    Respir Res; 2023 Dec; 24(1):317. PubMed ID: 38104128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention.
    Cuthbertson L; Rogers GB; Walker AW; Oliver A; Green LE; Daniels TW; Carroll MP; Parkhill J; Bruce KD; van der Gast CJ
    ISME J; 2016 May; 10(5):1081-91. PubMed ID: 26555248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung.
    Sosinski LM; H CM; Neugebauer KA; Ghuneim LJ; Guzior DV; Castillo-Bahena A; Mielke J; Thomas R; McClelland M; Conrad D; Quinn RA
    J Cyst Fibros; 2022 Nov; 21(6):996-1005. PubMed ID: 34824018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
    Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
    Res Sq; 2023 Sep; ():. PubMed ID: 37841851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Associations of the Cystic Fibrosis Airway Microbiome and Volatile Metabolites: A Case Study.
    Hahn A; Whiteson K; Davis TJ; Phan J; Sami I; Koumbourlis AC; Freishtat RJ; Crandall KA; Bean HD
    Front Cell Infect Microbiol; 2020; 10():174. PubMed ID: 32411616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic footprint of the airway bacterial community in cystic fibrosis.
    Narayanamurthy V; Sweetnam JM; Denner DR; Chen LW; Naureckas ET; Laxman B; White SR
    Microbiome; 2017 Jun; 5(1):67. PubMed ID: 28666467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.
    Reid DW; Latham R; Lamont IL; Camara M; Roddam LF
    J Cyst Fibros; 2013 Dec; 12(6):688-99. PubMed ID: 23706827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?
    Stressmann FA; Rogers GB; Marsh P; Lilley AK; Daniels TW; Carroll MP; Hoffman LR; Jones G; Allen CE; Patel N; Forbes B; Tuck A; Bruce KD
    J Cyst Fibros; 2011 Sep; 10(5):357-65. PubMed ID: 21664196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.
    Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G
    Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability.
    Caverly LJ; Lu J; Carmody LA; Kalikin LM; Shedden K; Opron K; Azar M; Cahalan S; Foster B; VanDevanter DR; Simon RH; LiPuma JJ
    Ann Am Thorac Soc; 2019 Dec; 16(12):1534-1542. PubMed ID: 31415187
    [No Abstract]   [Full Text] [Related]  

  • 13. Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome.
    Quinn RA; Phelan VV; Whiteson KL; Garg N; Bailey BA; Lim YW; Conrad DJ; Dorrestein PC; Rohwer FL
    ISME J; 2016 Jun; 10(6):1483-98. PubMed ID: 26623545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotics Drive Expansion of Rare Pathogens in a Chronic Infection Microbiome Model.
    Varga JJ; Zhao CY; Davis JD; Hao Y; Farrell JM; Gurney JR; Voit E; Brown SP
    mSphere; 2022 Oct; 7(5):e0031822. PubMed ID: 35972133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophilic proteolysis in the cystic fibrosis lung correlates with a pathogenic microbiome.
    Quinn RA; Adem S; Mills RH; Comstock W; DeRight Goldasich L; Humphrey G; Aksenov AA; Melnik AV; da Silva R; Ackermann G; Bandeira N; Gonzalez DJ; Conrad D; O'Donoghue AJ; Knight R; Dorrestein PC
    Microbiome; 2019 Feb; 7(1):23. PubMed ID: 30760325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sputum DNA sequencing in cystic fibrosis: non-invasive access to the lung microbiome and to pathogen details.
    Feigelman R; Kahlert CR; Baty F; Rassouli F; Kleiner RL; Kohler P; Brutsche MH; von Mering C
    Microbiome; 2017 Feb; 5(1):20. PubMed ID: 28187782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Microbiome and Metabolome of Preterm Infant Stool Are Personalized and Not Driven by Health Outcomes, Including Necrotizing Enterocolitis and Late-Onset Sepsis.
    Wandro S; Osborne S; Enriquez C; Bixby C; Arrieta A; Whiteson K
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplemental Oxygen Alters the Airway Microbiome in Cystic Fibrosis.
    Vieira J; Jesudasen S; Bringhurst L; Sui HY; McIver L; Whiteson K; Hanselmann K; O'Toole GA; Richards CJ; Sicilian L; Neuringer I; Lai PS
    mSystems; 2022 Oct; 7(5):e0036422. PubMed ID: 36000724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.
    Tunney MM; Field TR; Moriarty TF; Patrick S; Doering G; Muhlebach MS; Wolfgang MC; Boucher R; Gilpin DF; McDowell A; Elborn JS
    Am J Respir Crit Care Med; 2008 May; 177(9):995-1001. PubMed ID: 18263800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biogeochemical forces shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung.
    Quinn RA; Lim YW; Maughan H; Conrad D; Rohwer F; Whiteson KL
    mBio; 2014 Mar; 5(2):e00956-13. PubMed ID: 24643867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.